Eric D Hsi Selected Research

enavatuzumab

2/2013	Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb.
1/2010	Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric D Hsi Research Topics

Disease

50	Neoplasms (Cancer) 05/2022 - 06/2002
40	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 03/2022 - 06/2006
38	Lymphoma (Lymphomas) 04/2022 - 01/2002
19	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 01/2007
13	Hodgkin Disease (Hodgkin's Disease) 10/2020 - 06/2005
10	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2020 - 11/2008
9	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2021 - 08/2002
8	Leukemia 01/2021 - 07/2005
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2020 - 07/2005
7	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2020 - 08/2004
6	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2022 - 01/2007
6	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022 - 01/2007
6	Disease Progression 01/2018 - 08/2011
6	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2016 - 07/2005
6	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 11/2014 - 10/2003
5	Multiple Myeloma 01/2020 - 08/2004
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 08/2014 - 03/2003
3	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 11/2022 - 01/2002
3	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2019 - 04/2011
2	Isochromosomes 05/2022 - 01/2022
2	B-Cell Leukemia (Leukemia, B Cell) 11/2020 - 06/2014
2	Neutropenia 10/2019 - 10/2019
2	Nausea 10/2019 - 07/2014
2	Anemia 10/2019 - 01/2017
2	Residual Neoplasm 10/2017 - 04/2012
2	Infections 10/2017 - 04/2004
2	Genetic Translocation (Chromosomal Translocation) 10/2014 - 11/2009
2	Fever (Fevers) 01/2013 - 04/2004
2	Plasma Cell Neoplasms 08/2011 - 10/2009
1	Colitis 09/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022
1	Thyroid Neoplasms (Thyroid Cancer) 01/2022

Drug/Important Bio-Agent (IBA)

21	Rituximab (Mabthera)FDA Link 01/2019 - 01/2008
20	Proteins (Proteins, Gene)FDA Link 01/2021 - 06/2006
16	Biological ProductsIBA 05/2022 - 03/2007
12	Biomarkers (Surrogate Marker)IBA 04/2022 - 10/2004
9	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 12/2010
9	Vincristine (Oncovin)FDA LinkGeneric 01/2019 - 12/2010
9	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 12/2010
9	Prednisone (Sone)FDA LinkGeneric 01/2019 - 12/2010
7	Cyclin D1IBA 01/2019 - 04/2006
6	DNA (Deoxyribonucleic Acid)IBA 03/2022 - 06/2002
6	AntibodiesIBA 01/2019 - 11/2003
6	Monoclonal AntibodiesIBA 11/2014 - 04/2004
5	enzastaurinIBA 01/2016 - 07/2009
5	ParaffinIBA 04/2015 - 03/2003
4	Bortezomib (Velcade)FDA Link 01/2020 - 08/2004
4	CyclinsIBA 01/2019 - 04/2006
4	Formaldehyde (Formol)FDA Link 04/2015 - 04/2006
3	venetoclaxIBA 11/2020 - 10/2016
3	Pharmaceutical PreparationsIBA 01/2020 - 04/2007
3	ibrutinibIBA 12/2019 - 03/2015
3	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 10/2019 - 08/2002
3	CytokinesIBA 01/2019 - 04/2007
3	LigandsIBA 01/2019 - 01/2008
3	Membrane Proteins (Integral Membrane Proteins)IBA 01/2018 - 10/2003
3	Immunoglobulins (Immunoglobulin)IBA 10/2017 - 03/2003
3	Indicators and Reagents (Reagents)IBA 01/2017 - 07/2007
3	AntigensIBA 12/2016 - 04/2004
3	Histone Deacetylase InhibitorsIBA 10/2013 - 07/2010
3	Messenger RNA (mRNA)IBA 11/2009 - 03/2003
3	AnthracyclinesIBA 01/2008 - 08/2004
2	RNA (Ribonucleic Acid)IBA 03/2022 - 01/2018
2	Phosphotransferases (Kinase)IBA 01/2021 - 07/2007
2	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 01/2021 - 09/2014
2	Cytidine DeaminaseIBA 01/2021 - 01/2016
2	IgKIBA 10/2019 - 11/2009
2	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 01/2019 - 04/2006
2	Etoposide (VP 16)FDA LinkGeneric 01/2019 - 05/2012
2	Anaplastic Lymphoma KinaseIBA 01/2019 - 08/2014
2	Bleomycin (Blenoxane)FDA LinkGeneric 01/2018 - 05/2011
2	Immunoconjugates (Immunoconjugate)IBA 01/2018 - 01/2018
2	Leucine (L-Leucine)FDA Link 01/2018 - 01/2018
2	Immunoglobulin M (IgM)IBA 01/2018 - 10/2017
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2018 - 10/2007
2	Tyrosine Kinase InhibitorsIBA 01/2018 - 01/2016
2	Vinblastine (Vinblastine Sulfate)FDA Link 01/2018 - 05/2011
2	Dacarbazine (DIC)FDA LinkGeneric 01/2018 - 05/2011
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2017 - 01/2016
2	NF-kappa B (NF-kB)IBA 12/2016 - 10/2003
2	Protein Kinase CIBA 01/2016 - 10/2013
2	MicroRNAs (MicroRNA)IBA 06/2015 - 07/2011
2	Immunoglobulin G (IgG)IBA 09/2013 - 01/2010
2	TWEAK ReceptorIBA 02/2013 - 01/2010
2	enavatuzumabIBA 02/2013 - 01/2010
2	Histone Deacetylases (Histone Deacetylase)IBA 09/2011 - 07/2010
2	Gemcitabine FDA Link 05/2011 - 06/2008
2	Thomsen-Friedenreich antibodiesIBA 11/2003 - 01/2002
1	CateninsIBA 09/2022
1	selpercatinibIBA 01/2022
1	Decitabine FDA Link 01/2021
1	Azacitidine (5 Azacytidine)FDA Link 01/2021

Therapy/Procedure

36	Therapeutics 11/2022 - 01/2002
12	Drug Therapy (Chemotherapy) 01/2020 - 01/2002
6	Stem Cell Transplantation 01/2020 - 11/2008
5	Immunotherapy 01/2019 - 01/2002
3	Radiotherapy 10/2020 - 09/2013
2	VAP-cyclo protocol 10/2015 - 12/2010
1	Photopheresis 11/2022
1	Biological Therapy 01/2021